• 1. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindolones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindolines Isoindolones

Introduction to Lurasidone INT 1 and CAS No. 14805-29-9

Lurasidone INT 1 is a significant compound in the field of pharmaceutical chemistry, with its chemical structure and properties playing a crucial role in the development of innovative treatments for neurological and psychiatric disorders. The compound is identified by the CAS number CAS NO. 14805-29-9, which serves as a unique identifier for its molecular composition and characteristics. This introduction delves into the compound's chemical properties, its applications in medical research, and recent advancements in understanding its mechanisms of action.

The molecular formula of Lurasidone INT 1 is C₁₉H₂₂N₂O_{2, reflecting its complex structure that includes various functional groups essential for its pharmacological activity. These groups contribute to its binding affinity and selectivity, making it an effective candidate for therapeutic intervention. The compound's solubility, stability, and metabolic pathways are critical factors that influence its efficacy and safety profile, areas extensively studied in recent years.}

In the realm of pharmaceutical research, Lurasidone INT 1 has garnered attention for its potential in treating conditions such as schizophrenia and bipolar disorder. Its unique mechanism of action involves modulating dopamine and serotonin receptors, which are key neurotransmitters involved in regulating mood and cognitive functions. Recent studies have highlighted the compound's ability to reduce negative symptoms associated with these disorders, offering new hope for patients who have not responded well to traditional treatments.

One of the most compelling aspects of Lurasidone INT 1 is its distinct pharmacokinetic profile. Unlike many antipsychotic drugs that exhibit high affinity for dopamine D₂ receptors, Lurasidone INT 1 demonstrates a more balanced receptor occupancy across multiple neurotransmitter systems. This balance is thought to contribute to its reduced risk of side effects such as extrapyramidal symptoms (EPS) and weight gain, which are commonly observed with other antipsychotics. The compound's ability to achieve this balance without compromising therapeutic efficacy has made it a subject of intense interest among researchers.

Advances in analytical chemistry have enabled more precise characterization of Lurasidone INT 1, facilitating better understanding of its interactions within biological systems. Techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and X-ray crystallography have been instrumental in elucidating its three-dimensional structure and dynamics. These insights have not only enhanced our comprehension of the compound's pharmacological effects but also provided valuable information for designing analogs with improved properties.

The development of Lurasidone INT 1 has also been influenced by computational methods, including molecular modeling and virtual screening. These approaches allow researchers to predict how the compound interacts with biological targets at an atomic level, thereby accelerating the drug discovery process. By integrating experimental data with computational predictions, scientists can refine their understanding of Lurasidone INT 1's mechanism of action and optimize its pharmacological profile.

In clinical trials, Lurasidone INT 1 has demonstrated promising results in treating both acute exacerbations and long-term management of psychiatric disorders. Its efficacy in reducing hallucinations, delusions, and cognitive impairments has been well-documented, making it a valuable addition to the treatment arsenal for patients suffering from these conditions. Moreover, its favorable side effect profile has improved patient adherence and overall treatment satisfaction.

The future direction of research on Lurasidone INT 1 includes exploring its potential in treating other neurological disorders beyond schizophrenia and bipolar disorder. Preliminary studies suggest that it may have applications in conditions such as depression and anxiety disorders due to its modulatory effects on serotonin receptors. Additionally, investigating the compound's long-term safety profile will be essential to ensure its sustained clinical relevance.

In conclusion, Lurasidone INT 1 represents a significant advancement in the field of psychiatric medications. Its unique chemical properties, coupled with recent findings from clinical research, underscore its potential as a therapeutic agent for various neurological disorders. As our understanding of brain chemistry continues to evolve, compounds like Lurasidone INT 1 will play an increasingly vital role in shaping the future of mental health treatment.

• 70265-07-5(1H-Isoindole-1,3(2H)-dione, hexahydro-, trans-)
• 85922-86-7(cis-4-Azatricyclo[5.2.2.0 {2,6}]undecane-3,5- dione)
• 27800-93-7([5,5'-Bi-1H-isoindole]-1,1',3,3'(2H,2'H)-tetrone, dodecahydro-)
• 5763-44-0(1,2-Cyclopentanedicarboximide)
• 63485-40-5(1H-Isoindole-1,3(2H)-dione, hexahydro-5-methyl-)
• 22031-22-7(1H-Cyclopenta[1,2-c:3,4-c']dipyrrole-1,3,4,6(2H,3aH,5H)-tetrone,tetrahydro- (9CI))
• 15774-55-7((3aR,3bS,6aS,7aR)-tetrahydro-1H-cyclopenta[1,2-c:3,4-c']dipyrrole-1,3,4,6(2H,3aH,5H)-tetrone)
• 1444-94-6(octahydro-1H-isoindole-1,3-dione)
• 7506-66-3(cis-Hexahydro-1H-isoindole-1,3(2H)-dione)
• 28871-95-6(Endo-2,3-Norbornanedicarboximide)